El interés en corto de Gain Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Gain Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Gain Therapeutics (NASDAQ:GANX) Bolsa, Informe de interés en corto

Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

AZTR

GANX

SILO

Descubre las últimas transacciones de insiders en penny stocks como ALZN, GANX, AZTR y SILO. ¡Aprovecha esta información privilegiada ahora!

Compras de insiders de penny stocks: ALZN, GANX, AZTR, SILO

Gain Therapeutics Inc

Grown Rogue International Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GRIN#CSE">GRIN</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRUSF#OTC">GRUSF</a>) reported its third quarter 2024 results on Thursday for the three months ended Sept. 30, 2024.
"This was another exciting quarter for Grown Rogue with solid financial metrics showing the continued execution by our team in competitive markets against a backdrop of modest price compression," CEO Obie Strickler said. "We continue to see strong indoor production yields of craft-quality flower, retail buyer and consumer loyalty, and great initial reception and sell-through with our branded pre-rolls, including our newest brand Yeti."
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
The comparison period for 2023 is the three months ended Oct. 31, 2023, due to the fiscal year-end change from Oct. 31 to Dec. 31. 
<ul>
<li>Revenue totaled $7 million, up 7% compared to $6.5 million in the fourth quarter of 2023.</li>
<li>Gross profit amounted to $3.9 million, a decrease from $4.4 million in Q4 2023, primarily due to lower margins in Oregon and pricing pressures.</li>
<li>Adjusted EBITDA was positive at $2.1 million, unchanged from the previous quarter. Its margin was 30%, down 210 basis points from the fourth quarter of 2023.</li>
<li>Operating cash flow was $1.21 million, down 24% from $1.5 million in the fourth quarter of 2023. The decrease was attributed to increased spending on the New Jersey market launch.</li>
<li>Operating expenses increased by 35% to $2.95 million due to higher selling, general and administrative expenses.</li>
<li>The net loss was $667,240, an improvement from the $2.01 million recorded in the same period last year.</li>
<li>Cash and cash equivalents totaled $5.6 million, down from $6.8 million as of Dec. 31, 2023.</li>
<li>Positive cash flow of $5.01 million for the quarter.</li>
<li>Total assets grew to $41.3 million, up from $29.6 million at year-end 2023.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40576446/grown-rogue-cannabis-reports-record-q2-revenue-and-adjusted-ebitda-nj-and-illinois-major-growth-">Grown Rogue Cannabis Reports Record Q2 Revenue And Adjusted EBITDA, NJ And Illinois Major Growth Drivers</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Other Business Highlights</h3>
In New Jersey, Grown Rogue announced competition of the company's first harvest in the state, with product drops expected in Dec. 2024. The company is optimistic about generating significant cash flow from this market.
It also announced the commencement of phase I operations in the Garden State, which includes roughly 8,000 square feet of flowering canopy that will produce 500-600 pounds of whole flower per month with sales anticipated in the fourth quarter of 2024.
In Illinois, phase II construction is progressing, with a target of 1,100 pounds of whole flower production per month once completed in mid-2025.
Subsequent to quarter-end, the company announced the termination of an advisory agreement with Vireo Growth Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VREOF#OTC">VREOF</a>).
<h3 class="wp-block-heading">Outlook</h3>
Grown Rogue said it will focus on its New Jersey and Illinois expansions as primary growth drivers for 2025.
Additionally, Phase II of the New Jersey operation is expected to be completed by mid-2025, with the Illinois project following later in the year.
<h3 class="wp-block-heading">GRUSF Price Action</h3>
Grown Rogue's shares traded 2.94% higher at 7 cents per share after the market close on Thursday afternoon.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41284994/grown-rogue-secures-800k-vireo-forfeits-4-5m-warrants-in-cannabis-shakeup-whats-next-for-both">Grown Rogue Secures $800K, Vireo Forfeits 4.5M Warrants In Cannabis Shakeup—What&#8217;s Next For Both?</a></li>
</ul>

Cannabis

Earnings

CSE:GRIN

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

GRUSF

VREOF

Cannabis Co. Grown Rogue Reports 7% Increase In Q3 Revenue, Focuses On New Jersey And Illinois Expansion

TD Cowen analyst Oliver Chen maintains Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) with a Hold and raises the price target from $13 to $14.

Price Target

Analyst Ratings

TD Cowen Maintains Hold on Sally Beauty Holdings, Raises Price Target to $14

Citius Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 12,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of its common stock, at a purchase price of $0.25 per share and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $0.25 per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date.&nbsp; The closing of the offering is expected to occur on or about November 18, 2024, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be $3 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.

Offerings

CTXR

Citius Pharmaceuticals Entered Into Definitive Agreements For The Purchase Of An Aggregate Of 12M Shares Of Its Common Stock And Accompanying Warrants To Purchase Up To An Aggregate Of 12M Shares Of Its Common Stock, At A Purchase Price Of $0.25 Per Share And Accompanying Warrant In A $3M Registered Direct Offering

Whales with a lot of money to spend have taken a noticeably bullish stance on Expedia Group.
Looking at options history for Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $203,880 and 6, calls, for a total amount of $424,321.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $192.5 for Expedia Group over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Expedia Group stands at 475.71, with a total volume reaching 1,784.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Expedia Group, situated within the strike price corridor from $110.0 to $192.5, throughout the last 30 days.
<h3>Expedia Group Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731695489_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$21.5</td>
<td>$21.1</td>
<td>$21.5</td>
<td>$160.00</td>
<td>$107.6K</td>
<td>1.3K</td>
<td>151</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.95</td>
<td>$21.0</td>
<td>$21.28</td>
<td>$160.00</td>
<td>$106.4K</td>
<td>1.3K</td>
<td>51</td>
</tr>
<tr>
<td>EXPE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$1.43</td>
<td>$0.72</td>
<td>$0.74</td>
<td>$172.50</td>
<td>$88.8K</td>
<td>54</td>
<td>1.2K</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$21.3</td>
<td>$21.05</td>
<td>$21.3</td>
<td>$160.00</td>
<td>$78.8K</td>
<td>1.3K</td>
<td>101</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$41.75</td>
<td>$40.25</td>
<td>$40.81</td>
<td>$140.00</td>
<td>$65.2K</td>
<td>1.3K</td>
<td>16</td>
</tr>
</tbody>
</table>

<h3>About Expedia Group</h3>
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2023 sales), air tickets (3%), rental cars, cruises, in-destination, and other (11%), and advertising revenue (6%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Having examined the options trading patterns of Expedia Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Expedia Group</h3>
<ul>
<li>With a volume of 719,408, the price of EXPE is down -1.06% at $180.33. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>Expert Opinions on Expedia Group</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $173.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Expedia Group, targeting a price of $210. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Expedia Group, targeting a price of $166. 
&#x2A; An analyst from Jefferies persists with their Hold rating on Expedia Group, maintaining a target price of $160. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Expedia Group with a target price of $153. 
&#x2A; An analyst from Wedbush persists with their Neutral rating on Expedia Group, maintaining a target price of $180. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Expedia Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

EXPE

Expedia Group Options Trading: A Deep Dive into Market Sentiment

Compass Point analyst Casey Alexander maintains Blackstone Secured (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXSL#NYSE">BXSL</a>) with a Buy and lowers the price target from $33.5 to $32.25.

BXSL

Compass Point Maintains Buy on Blackstone Secured, Lowers Price Target to $32.25

High-rolling investors have positioned themselves bullish on Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CHTR often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 14 options trades for Charter Communications. This is not a typical pattern.
The sentiment among these major traders is split, with 35% bullish and 7% bearish. Among all the options we identified, there was one put, amounting to $36,400, and 13 calls, totaling $389,626.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $130.0 and $400.0 for Charter Communications, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Charter Communications's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Charter Communications's substantial trades, within a strike price spectrum from $130.0 to $400.0 over the preceding 30 days.
<h3>Charter Communications Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731695484_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$152.6</td>
<td>$151.3</td>
<td>$151.3</td>
<td>$300.00</td>
<td>$75.6K</td>
<td align="right">722</td>
<td align="right">12</td>
</tr>
<tr>
<td>CHTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$75.0</td>
<td>$72.8</td>
<td>$72.8</td>
<td>$400.00</td>
<td>$36.4K</td>
<td align="right">918</td>
<td align="right">12</td>
</tr>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$265.8</td>
<td>$257.7</td>
<td>$262.21</td>
<td>$130.00</td>
<td>$26.2K</td>
<td align="right">0</td>
<td align="right">13</td>
</tr>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$264.8</td>
<td>$257.6</td>
<td>$262.21</td>
<td>$130.00</td>
<td>$26.2K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>CHTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$262.5</td>
<td>$257.7</td>
<td>$262.15</td>
<td>$130.00</td>
<td>$26.2K</td>
<td align="right">0</td>
<td align="right">18</td>
</tr>
</tbody>
</table>

<h3>About Charter Communications</h3>
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 58 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
In light of the recent options history for Charter Communications, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Charter Communications's Current Market Status</h3>
<ul>
<li>With a volume of 452,368, the price of CHTR is down -0.95% at $390.52. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Charter Communications</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $386.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Charter Communications, targeting a price of $400. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Underweight rating on Charter Communications with a target price of $315. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Charter Communications, maintaining a target price of $400. 
&#x2A; Showing optimism, an analyst from B of A Securities upgrades its rating to Buy with a revised price target of $450. 
&#x2A; An analyst from Deutsche Bank persists with their Hold rating on Charter Communications, maintaining a target price of $365. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Charter Communications options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CHTR

Spotlight on Charter Communications: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CPRI usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Capri Holdings. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 7 are puts, totaling $238,026, and 3 are calls, amounting to $132,484.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $42.5 for Capri Holdings over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Capri Holdings options trades today is 1805.0 with a total volume of 1,847.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Capri Holdings's big money trades within a strike price range of $15.0 to $42.5 over the last 30 days.
<h3>Capri Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731695479_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$19.8</td>
<td>$19.2</td>
<td>$19.4</td>
<td>$40.00</td>
<td>$64.0K</td>
<td>10.3K</td>
<td align="right">35</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.4</td>
<td>$1.25</td>
<td>$1.4</td>
<td>$20.00</td>
<td>$55.7K</td>
<td>1.7K</td>
<td align="right">436</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$15.00</td>
<td>$46.2K</td>
<td>96</td>
<td align="right">70</td>
</tr>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$22.3</td>
<td>$21.4</td>
<td>$21.94</td>
<td>$42.50</td>
<td>$32.9K</td>
<td>75</td>
<td align="right">15</td>
</tr>
<tr>
<td>CPRI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.5</td>
<td>$17.1</td>
<td>$17.22</td>
<td>$37.50</td>
<td>$30.9K</td>
<td>121</td>
<td align="right">33</td>
</tr>
</tbody>
</table>

<h3>About Capri Holdings</h3>
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Following our analysis of the options activities associated with Capri Holdings, we pivot to a closer look at the company's own performance.
<h3>Capri Holdings's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,261,855, the CPRI's price is up by 0.85%, now at $20.7. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<h3>What The Experts Say On Capri Holdings</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $27.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo downgraded its action to Equal-Weight with a price target of $42. 
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on Capri Holdings, which currently sits at a price target of $22. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Capri Holdings, targeting a price of $23. 
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Market Perform rating on Capri Holdings with a target price of $26. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Capri Holdings, targeting a price of $23. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Capri Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

CPRI

Market Whales and Their Recent Bets on CPRI Options

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) analysts Tom Narayan and Brad Erickson highlight the company's potential with FSD and robotaxis and also share thoughts on whether the electric vehicle giant could work with Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and Lyft Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) instead of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41295072/tesla-robotaxi-day-event-more-fanfare-than-substance-8-analysts-on-cybercab-optimus">competing against them.</a>
Tesla FSD, Autonomous Opportunity: RBC hosted investors at Tesla's Giga Texas facility and now has "increasing confidence" in the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41259841/uber-vs-tesla-maybe-not-analysts-say-autonomous-vehicles-will-be-market-expanding">company's autonomous vehicle goals</a>, along with more confidence in seeing the company's competitive advantages in manufacturing over other automotive companies.
Narayan and Erickson, who have an Outperform rating on Tesla, raised the price target from $249 to $313.
"While we think much of the stock's post-election share price move is not rooted in fundamentals, we like the risk/reward of our implied upside value/share versus our downside," the analysts said.
The analysts said the automotive sector remains challenging and Tesla stock could see near-term pressure, but has a chance for long-term growth thanks to FSD innovation. The analysts assign a value of $102 per share for Tesla's FSD business, cars represent $36 per share and robotaxis represent $136 per share.
The analysts said Donald Trump&#8216;s elimination of the electric vehicle credit could be a net negative for Tesla, which is expected to gain market share as a result.
Tesla's newest version of FSD includes a "hands-off" allowance for roads in the United States, which could put Tesla ahead of other competitors, the analysts said.
"Almost every OEM L2+ product in the market currently has limitations. Most do not take exits, make turns, and in some cases do automatic lane changes."
The analysts expect FSD pricing to come down to $50 per month for consumers, but see the future opportunity to increase the price to $100 per month with new features.
Tesla could earn $83 billion in revenue from FSD and could see $22 billion in licensing revenue for the software by 2035, the analysts said.
The analysts see FSD's value rising from $61 per share to $102 per share, representing 33% of the overall price target on Tesla and 64% of the price target increase.
RBC's tour of Giga Texas also led to a price increase on Tesla cars, thanks to the company's vertical integration and cost structure advantages over the competition.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/10/41501607/tesla-q3-earnings-highlights-eps-beat-revenue-miss-shares-climb-on-2025-timeline-for-lower-cost-evs">Tesla Q3 Earnings Highlights: EPS Beat, Revenue Miss, Shares Climb On 2025 Timeline For Lower-Cost EVs</a>
Robotaxi Opportunity: The analysts said Tesla is committed to owning all pieces of the robotaxi ecosystem, which includes the vehicle, software and app. This could give the company a competitive cost advantage over other autonomous vehicles, the analysts added.
Narayan and Erickson think Tesla could represent a 20% share of robotaxis in the U.S., 6% in Europe, and 8% in China.
While Tesla robotaxis could be bad news for ride-hail companies like Uber and Lyft, the analysts see an opportunity for the market size to grow and for potential partnerships.
"Ride volumes would increase dramatically, helped by lower pricing coming from AV ridesharing," the analysts said. "Currently, only 1% of miles driven in the U.S. for example, come from ridesharing."
Tesla has around two million vehicles on the road in the US and Uber has 70 million to 80 million active users, the analysts noted.
"As such, partnering with Uber makes sense to expand its customer base."
Erickson said he has "rising conviction" that Tesla could be more open to working with Uber and Lyft at some point.
"We believe the successful AV networks of the future will involve deeply integrated partnerships composed of OEMs, suppliers, software-enablers and ride-hailing networks all playing their critical roles in delivering a safe, reliable and, importantly, economically sustainable service."
Erickson said Uber and Lyft are likely to benefit from a growing total addressable market expansion for ride-hail and robotaxis with or without a partnership from Tesla.
"We believe Tesla is more mindful of maintaining some level of economic rationality than we might have thought previously and would view them more as a partnership candidate over time."
Without partnerships with Lyft and Uber, Tesla could have to spend tens of billions of dollars to reach "adequate marketplace density and liquidity."
RBC has an Outperform rating on Lyft with a $24 price target. RBC has an Outperform rating on Uber with an $82 price target.
TSLA, UBER, LYFT Price Action: Tesla stock is up 3% to $320.41 on Friday versus a 52-week trading range of $138.80 to $358.64. Tesla stock is up 29% year-to-date.
Uber stock is up 2% to $73.00 on Friday versus a 52-week trading range of $53.15 to $87.00. Uber stock is up 25% year-to-date.
Lyft stock is up 1% to $18.02 on Friday versus a 52-week trading range of $8.92 to $20.82. Lyft stock is up 31% year-to-date.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41985486/if-tesla-stock-hits-all-time-highs-in-2025-will-it-be-driven-by-trump-musk-relationship-benzinga-readers-say-this">If Tesla Stock Hits All-Time Highs In 2025, Will It Be Driven By Trump-Musk Relationship? Benzinga Readers Say This</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Reiteration

LYFT

TSLA

UBER

Tesla To Partner With Lyft, Uber? Analyst Has 'Rising Conviction' For Future Partnership

Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) faces a new shareholder lawsuit accusing the Canadian cannabis company of misleading voting practices for a second consecutive year. 
The legal complaint, filed on October 31, 2024 in the Delaware Court of Chancery, alleges that Tilray misled investors regarding the voting requirements to increase its authorized shares, <a href="https://www.investing.com/news/company-news/tilray-faces-shareholder-lawsuit-over-voting-standards-93CH-3707585">reported</a> Investing.com.
<h3 class="wp-block-heading">Disputed Voting Standards And Shareholder Allegations</h3>
According to the lawsuit, Tilray's proxy statements for the 2023 and 2024 annual meetings inaccurately presented the voting standards needed for approval. The plaintiff argues that the company required only a majority of votes cast, rather than a majority of all outstanding shares, to pass proposals that increased the number of authorized shares. This discrepancy, the complaint claims, invalidates the approval and subsequent issuances of new common stock.
The lawsuit contends that Tilray's board of directors breached their fiduciary duties by failing to provide accurate information.
The plaintiff seeks to block the company from holding a vote on the 2024 Authorized Shares Proposal at the upcoming annual meeting scheduled for November 21, 2024. Additionally, the lawsuit demands reimbursement of legal fees and related costs for the affected shareholders.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41997646/tilray-joins-german-cannabis-fiesta-with-first-locally-grown-strains">Tilray Joins German Cannabis Fiesta With First Locally Grown Strains</a>
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Tilray's Defense And Institutional Support</h3>
Tilray, however, firmly denies the allegations, stating that its voting practices comply with the 2023 amendments to Delaware's General Corporation Law. 
The company maintains that the lower threshold for stockholder approval aligns with legal standards for corporations listed on national exchanges. Tilray's management argues that the increase in authorized shares is necessary for enhancing financial flexibility and facilitating strategic acquisitions.
Institutional Shareholder Services (ISS) has endorsed Tilray's proposal, recommending shareholders vote in favor of the increase, citing no significant concerns over past share usage.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41273594/tilray-reports-200m-q1-net-revenue-up-13-yoy-as-net-loss-improves">Tilray Reports $200M Q1 Net Revenue, Up 13% YoY As Net Loss Improves</a></li>
</ul>
Cover: AI generated image

Legal

TLRY

Shareholder Lawsuit Challenges Tilray's Voting Tactics For Authorized Share Increase

<a href="https://www.bloomberg.com/news/articles/2024-11-15/lucid-ceo-says-unprofitable-ev-maker-is-immune-from-trump-policy-changes">https://www.bloomberg.com/news/articles/2024-11-15/lucid-ceo-says-unprofitable-ev-maker-is-immune-from-trump-policy-changes</a>
Lucid Group Inc.'s chief executive downplayed the significance of US electric vehicle tax credits for the company, even as concerns about the potential loss of subsidies sent the EV maker's shares to new lows.

LCID

Reported Earlier, 'Lucid CEO Says EV Maker Mostly Immune If Trump Nixes Tax Credit' - Bloomberg News

BTIG analyst Gregory Lewis maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and raises the price target from $15 to $19.

Core Scientific, Inc. - Class A Common Stock

CORZ

BTIG Maintains Buy on Core Scientific, Raises Price Target to $19

WIIM

McDonalds shares are trading lower after the company announced it will spend $100 million to move past the E. Coli outbreak it experienced at some of its stores.

BTIG analyst Gregory Lewis maintains Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Buy and raises the price target from $6 to $9.

CIFR

BTIG Maintains Buy on Cipher Mining, Raises Price Target to $9

The U.S. Treasury Department has released its <a href="https://www.fincen.gov/frequently-requested-foia-processed-records">quarterly report</a>, revealing that last year, over 830 financial institutions nationwide have officially acknowledged relationships with state-licensed cannabis businesses. According to a <a href="https://norml.org/news/2024/11/14/treasury-report-over-800-banking-institutions-report-relationships-with-state-licensed-cannabis-businesses/?link_id=5&amp;can_id=23ddea46021350bb8012464da757f45b&amp;source=email-norml-news-of-the-week-11142024&amp;email_referrer=email_2530540&amp;email_subject=norml-news-of-the-week-11142024">report</a> from the National Organization for the Reform of Marijuana Laws (NORML), this number reflects a modest increase from the previous year and represents nearly double the number of banks and credit unions engaged with the cannabis sector in 2018.
However, despite this growth, fewer than 10% of all financial institutions in the U.S. currently provide services to the <a href="https://www.benzinga.com/cannabis">cannabis industry</a>. The ongoing hesitation among banks stems from federal law, which classifies marijuana as a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I controlled substance</a>. This classification poses significant legal risks for banks, even when working with businesses fully compliant with state cannabis regulations.
<h3 class="wp-block-heading">Legislative Stalemate Continues To Hinder Progress</h3>
Efforts to resolve the banking issue have <a href="https://www.benzinga.com/markets/cannabis/24/07/39730510/house-gop-divided-over-cannabis-strikes-banking-protections-from-bill-respect-the-will-of-these-">repeatedly stalled in Congress</a>. The U.S. House of Representatives has passed legislation seven times to <a href="https://www.benzinga.com/topic/secure-and-fair-enforcement-safe-banking-act">protect financial institutions</a> that serve cannabis businesses from federal penalties. Yet, the Senate has <a href="https://www.benzinga.com/markets/cannabis/24/06/39324658/gop-controlled-house-strips-cannabis-banking-protections-from-government-spending-bill-in-blow-t">failed to advance</a> these proposals to a floor vote, leaving the cannabis industry in a precarious financial position.
The lack of clear federal guidelines continues to deter many banks, exacerbating the challenges faced by cannabis businesses in securing banking services and investment capital. According to a survey by Whitney Economics, <a href="https://www.benzinga.com/markets/cannabis/22/01/25324529/survey-72-of-cannabis-operators-say-lack-of-banking-is-biggest-problem-even-fewer-are-making-pro">over 70% of cannabis operators</a> cited limited access to banking and capital as their primary obstacle.
<h3 class="wp-block-heading">Impact On Smaller And Minority-Owned Businesses</h3>
The absence of comprehensive banking reform disproportionately impacts smaller and minority-owned cannabis businesses, which often rely on traditional financing to grow and operate. NORML, the first cannabis advocacy group in U.S., has called on Congress to amend federal banking laws. "No industry can operate safely, transparently, or effectively without access to banks or other financial institutions. The players in this industry, particularly smaller and minority-owned businesses, and their consumers will remain severely hampered without better access to credit and financing," said NORML deputy director Paul Armentano.
The lack of federal legalization and banking access for cannabis has <a href="https://www.benzinga.com/markets/cannabis/23/04/31671933/is-the-cannabis-industry-ignoring-minority-communities">disproportionately impacted minorities</a> and small businesses. Many entrepreneurs, especially from marginalized communities, face significant barriers to entry in the cannabis industry due to limited access to financial services, such as loans and credit. This forces many to operate in cash, increasing risks and operational difficulties. Additionally, the continued federal prohibition contributes to <a href="https://www.benzinga.com/markets/cannabis/22/08/28566915/racism-blossoms-in-states-with-criminal-penalties-for-cannabis-possession">racial disparities in arrests</a> and convictions related to cannabis, even as legalization spreads at the state level. Without full legalization and banking reform, these barriers hinder economic opportunities for minority business owners and perpetuate systemic inequities.
<h3 class="wp-block-heading">The Path Forward: SAFER Banking Act</h3>
The <a href="https://www.benzinga.com/topic/safer-banking-act">SAFER Banking Act</a> remains a key focus for cannabis advocates, who argue that it would provide the much-needed clarity and legal protection for financial institutions willing to work with the industry. The bill&#8217;s future remains tied to the broader <a href="https://www.benzinga.com/topic/cannabis-rescheduling">debate over federal cannabis policy</a>, and advocates <a href="https://www.benzinga.com/markets/cannabis/24/10/41133218/house-democrats-urge-dea-to-speed-up-cannabis-rescheduling">continue to push for its passage</a> to ensure safer, more equitable conditions for cannabis businesses across the U.S. For now, the limited participation of banks underscores the persistent legal uncertainty surrounding cannabis, even as the industry continues to expand across state markets.
Cover image made with AI

Treasury Report: Over 800 Banks Partnered With Cannabis Companies In 2023 Despite Federal Hurdles

BTIG analyst Gregory Lewis maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Buy and raises the price target from $16 to $20.

BTIG Maintains Buy on Bloom Energy, Raises Price Target to $20

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) plans to challenge recent court decisions that allow several states and hundreds of school districts across the United States to proceed with lawsuits.
These legal actions accuse Meta's <a target="_blank" href="https://www.benzinga.com/news/24/10/41349398/mark-zuckerbergs-meta-to-face-lawsuits-over-teen-social-media-addiction-judge-rejects-dismissal-moti" rel="noreferrer noopener">social media platforms</a>, including Facebook and Instagram, of contributing to a mental health crisis among young users.
The company filed appeals late Thursday, seeking a review by the U.S. Ninth Circuit Court of Appeals.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41981957/meta-hit-with-841-million-eu-fine-over-antitrust-violations-tied-to-facebook-marketplace" rel="noreferrer noopener">Meta Hit With $841 Million EU Fine Over Antitrust Violations Tied To Facebook Marketplace</a>
The appeals follow separate rulings by a federal judge in California last month, which rejected Meta's requests to dismiss the lawsuits, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-15/meta-to-appeal-orders-letting-schools-states-sue-over-addiction?srnd=homepage-Americas&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>.
U.S. District Judge Yvonne Gonzalez Rogers ruled in favor of 34 state attorneys general who argued that Meta's social media platforms, Facebook and Instagram, have had detrimental effects on youth mental health, leading to claims of negligence and public harm.
However, Judge Rogers largely denied motions to dismiss negligence claims but limited specific allegations, referencing Section 230 of the Communications Decency Act.
Alongside Meta, other tech giants such as Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) were also named in lawsuits filed by various school districts.
TikTok&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/10/41243023/tiktok-gets-sued-13-states-and-dc-accuse-chinese-platform-of-boosting-corporate-profits-via-social-m" rel="noreferrer noopener">faces regulatory action</a> from&nbsp;13 U.S. states and the&nbsp;District of Columbia for allegedly harming the youth.
Meta's legal team is moving forward with the appeal. The company argues that its platforms are not directly responsible for the alleged mental health issues, citing protections under existing internet laws.
Meta, Snap, and TikTok jointly launched Thrive to <a target="_blank" href="https://www.benzinga.com/news/24/09/40846628/meta-snap-and-tiktok-come-together-to-combat-suicide-and-self-harm-content-online-will-share-signals" rel="noreferrer noopener">tackle the spread</a> of harmful content related to self-harm and suicide on their platforms.
The program enables these social media companies to share alerts about graphic content, enhancing efforts to limit its reach.
The Mental Health Coalition collaborates with companies to help address concerns and reduce the stigma around mental health issues online.
Meta reported removing over 12 million posts related to suicide and self-harm on Facebook and Instagram between April and June this year.
Recently, <a target="_blank" href="https://www.benzinga.com/general/social-media/24/11/41862616/meta-ceo-mark-zuckerberg-dodges-personal-liability-in-child-social-media-addiction-lawsuits-federal-judge-cites-lack-of-evidence" rel="noreferrer noopener">Rogers ruled</a> that Meta CEO Mark Zuckerberg is not personally liable in 25 lawsuits alleging social media addiction among children.
Judge Yvonne Gonzalez Rogers dismissed claims suggesting Zuckerberg ignored internal warnings about mental health risks on Facebook and Instagram.
The plaintiffs argued that Zuckerberg downplayed the dangers, but the judge cited insufficient evidence of his direct involvement.
The ruling only applies to claims against Zuckerberg, while similar legal challenges against Meta remain unaffected.
Price Action: META stock is down 3.73% at $555.66 at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41978712/asml-projects-revenue-surge-to-63-billion-by-2030-eyes-ai-and-chip-market-boom" target="_blank" rel="noreferrer noopener">ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Tech

Media

GOOGL

SNAP

Meta Wants To Fight Back Order Allowing States and Schools To Sue Over Social Media Addiction

Brookline Capital analyst Kemp Dolliver downgrades Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) from Buy to Hold.

Downgrades

EYEN

Brookline Capital Downgrades Eyenovia to Hold

ABUS

Barinthus Biotherapeutics shares are trading lower. The company announced data from the ongoing Phase 2b HBV003 clinical trial.

DBGI

Digital Brands Group shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year decline in Q3 revenue.

Citigroup analyst Keith Horowitz maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Buy and raises the price target from $50 to $55.

ALLY

Citigroup Maintains Buy on Ally Financial, Raises Price Target to $55

Gain Therapeutics (GANX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

Buy Rating Affirmed for Gain Therapeutics on Promising Phase 1 Results and Solid Financial Outlook

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price target at $5.00...

Optimistic Buy Rating for Gain Therapeutics' GT-02287 Based on Promising Parkinson's Disease Treatment Potential

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price target at $8...

Buy Rating Affirmed for Gain Therapeutics' GT-02287 on Promising Phase 1 Results and Potential in Parkinson's Disease Treatment

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report), with a price...

Buy Rating Affirmed for Gain Therapeutics on GT-02287's Promising Parkinson's Disease Trial Data and Solid Financials

Gain Therapeutics ( ($GANX) ) has provided an update. Gain Therapeutics, Inc. revealed promising preclinical results for their drug candidate GT-02...

Gain Therapeutics Excels in Neurodegenerative Drug Trials

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Black Diamond Therapeutics (BDTX – Research Report),...

Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)

Gain Therapeutics (GANX) announced the presentation of a poster at the 36th EORTC-NCI-AACR, ENA, Symposium on molecular targets and cancer therapeu...

Gain Therapeutics presents data at 36th ENA symposium

"The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson'...

Gain Therapeutics reports Q3 EPS (17c), consensus (21c)

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS –&nbsp; Gain Therapeutics&nbsp;...

Closing Bell Movers: Applied Materials down 6% after earnings, guidance

Gain Therapeutics GAAP EPS of -$0.17

AKYA

AMAT

ASND

ASTS

BDTX

CELC

DESP

DMRC

FLNT

GLOB

HOOK

INKT

IZEA

MSGM

OKLO

ORGN

POOL

SRFM

Press Releases

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

General

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics to Participate at Upcoming Investor Conferences

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference

Health Care

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

Comments

Gain Therapeutics

Interés en corto

Gain Therapeutics (NASDAQ:GANX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL